新辅助治疗重焕生机:免疫治疗在头颈鳞癌的术前应用
表1正在进行和最近公布的新辅助免疫疗法试验
◆ 新辅助治疗的持续时间?
1.Stafford, Margaret,and John Kaczmar. “The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy inHNSCC.” Cancers of the head & neck vol.5 4. 16 Mar 2020, doi: 10. 1186 / s41199-020-00052-8.
2.Uppaluri R, Zolkind P,Lin T, Nussenbaum B, Jackson RS, Rich J, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma(HNSCC) J Clin Oncol. 2017;35(15Suppl):abstr 6012. doi: 10. 1200 /JCO .2017 .35. 15 _suppl.6012.
3.Horton J, KnochelmannH, Armeson K, Kaczmar J, Paulos C, Neskey D. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. J Clin Oncol. 2019; 37 (15_suppl) : 2574.
4.Ferris RL,Gonçalves A, Baxi AA, Martens UM, Gauthier H. An open-label,multicohort,phase 1/2 study in patients with virus-associated cancers(CheckMate 358): safety and efficacy ofneoadjuvant nivolumab in squamouscell carcinoma of the head and neck (SCCHN) Ann Oncology . 2017 ;28 (suppl_5):v605–V649.
5.Zuur CL, Elbers JBW,Vos JL, van der Leun A, Qiao X, Karakullukcu B, et al. Feasibility and toxicity of neoadjuvantnivolumab with or without ipilimumabprior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial,NCT03003637). J Clin Oncol. 2019;37(15_suppl):2575.
精彩推荐:
- End -